Policy conflicts: Gene patents and health care in Canada

被引:8
作者
Caulfield, T [1 ]
机构
[1] Univ Alberta, Law Ctr 461, Hlth Law Inst, Canada Res Chair Hlth Law & Policy, Edmonton, AB T6G 2H5, Canada
关键词
human gene patents; health care; Canada; patent reform;
D O I
10.1159/000087959
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Several recent gene patent controversies have energized and refocused the human gene patent debate in Canada. These include the use of the Myriad test for breast cancer by the provinces, patenting of the Severe Acute Respiratory Syndrome virus and a recent Supreme Court decision rejecting the patenting of 'higher life forms'. These cases place the emerging policy conflicts between the innovation and commercialization agenda of the government and the desire to provide equitable access to health care in sharp focus. Another challenge faced by Canada is the powerful influence of the United States in policy decisions. Although these issues have raised awareness about the possibility of reforming the patent system, Parliament has yet to consider any of the suggested reforms of the Canadian patent system and there are no formal proposals pending. Copyright (c) 2005 S. Karger AG, Basel.
引用
收藏
页码:223 / 227
页数:5
相关论文
共 33 条
[1]   The Doha Declaration on the TRIPS Agreement and Public Health: Lighting a dark corner at the WTO [J].
Abbott, FM .
JOURNAL OF INTERNATIONAL ECONOMIC LAW, 2002, 5 (02) :469-505
[2]  
[Anonymous], BIOTECHNOLOGY STAT O
[3]  
[Anonymous], DUKE J COMP L
[4]  
[Anonymous], ETH PAT DNA
[5]  
*AUSTR LAW REF COM, 2002, TERM REF INT PROP RI
[6]  
BENZIE R, 2001, NATL POST 0920
[7]  
*BIOTECANADA, 2002, EC IMP BIOT IND CAN
[8]  
Buctuanon EM, 2001, NEW GENET SOC, V20, P25, DOI 10.1080/14636770124005
[9]  
BUECKERT D, 2003, CANADIAN PRESS 1007
[10]   Genetic technologies, health care policy and the patent bargain [J].
Caulfield, TA ;
Knoppers, BM ;
Gold, ER ;
Sheremeta, LE ;
Bridge, PJ .
CLINICAL GENETICS, 2003, 63 (01) :15-18